Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

438 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-world clinical outcomes and prognostic factors in Japanese patients with recurrent or metastatic squamous cell carcinoma of head and neck treated with chemotherapy plus cetuximab: a prospective observation study (JROSG12-2).
Yokota T, Ota Y, Fujii H, Kodaira T, Shimokawa M, Nakashima T, Monden N, Homma A, Ueda S, Akimoto T. Yokota T, et al. Among authors: shimokawa m. Int J Clin Oncol. 2021 Feb;26(2):316-325. doi: 10.1007/s10147-020-01817-4. Epub 2020 Oct 30. Int J Clin Oncol. 2021. PMID: 33125596
Status of treatment for the overall population of patients with stage IVb endometrial cancer, and evaluation of the role of preoperative chemotherapy: a retrospective multi-institutional study of 426 patients in Japan.
Eto T, Saito T, Shimokawa M, Hatae M, Takeshima N, Kobayashi H, Kasamatsu T, Yoshikawa H, Kamura T, Konishi I. Eto T, et al. Among authors: shimokawa m. Gynecol Oncol. 2013 Dec;131(3):574-80. doi: 10.1016/j.ygyno.2013.08.036. Epub 2013 Sep 7. Gynecol Oncol. 2013. PMID: 24016406
Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy.
Toyokawa G, Takenoyama M, Hirai F, Toyozawa R, Inamasu E, Kojo M, Morodomi Y, Shiraishi Y, Takenaka T, Yamaguchi M, Shimokawa M, Seto T, Ichinose Y. Toyokawa G, et al. Among authors: shimokawa m. Int J Clin Oncol. 2014 Aug;19(4):601-6. doi: 10.1007/s10147-013-0619-5. Epub 2013 Oct 26. Int J Clin Oncol. 2014. PMID: 24158772
Phase II study of docetaxel and S-1 (DS) as neoadjuvant chemotherapy for clinical stage III resectable gastric cancer.
Oki E, Emi Y, Kusumoto T, Sakaguchi Y, Yamamoto M, Sadanaga N, Shimokawa M, Yamanaka T, Saeki H, Morita M, Takahashi I, Hirabayashi N, Sakai K, Orita H, Aishima S, Kakeji Y, Yamaguchi K, Yoshida K, Baba H, Maehara Y. Oki E, et al. Among authors: shimokawa m. Ann Surg Oncol. 2014 Jul;21(7):2340-6. doi: 10.1245/s10434-014-3594-9. Epub 2014 Mar 7. Ann Surg Oncol. 2014. PMID: 24604583 Clinical Trial.
Early skin toxicity predicts better outcomes, and early tumor shrinkage predicts better response after cetuximab treatment in advanced colorectal cancer.
Kogawa T, Doi A, Shimokawa M, Fouad TM, Osuga T, Tamura F, Mizushima T, Kimura T, Abe S, Ihara H, Kukitsu T, Sumiyoshi T, Yoshizaki N, Hirayama M, Sasaki T, Kawarada Y, Kitashiro S, Okushiba S, Kondo H, Tsuji Y. Kogawa T, et al. Among authors: shimokawa m. Target Oncol. 2015 Mar;10(1):125-33. doi: 10.1007/s11523-014-0322-0. Epub 2014 May 27. Target Oncol. 2015. PMID: 24859798
Factors associated with effects of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory low-grade B cell non-Hodgkin lymphoma: single-institution experience with 94 Japanese patients in rituximab era.
Uike N, Choi I, Tsuda M, Haji S, Toyoda K, Suehiro Y, Abe Y, Hayashi T, Sawamoto H, Kaneko K, Shimokawa M, Nakagawa M. Uike N, et al. Among authors: shimokawa m. Int J Hematol. 2014 Oct;100(4):386-92. doi: 10.1007/s12185-014-1636-5. Epub 2014 Aug 21. Int J Hematol. 2014. PMID: 25142378
438 results